相似文献
1
MRI in monitoring the treatment of multiple sclerosis: concerted action guidelines.
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):978. doi: 10.1136/jnnp.55.10.978.
2
In vivo characterization of the multiple sclerosis plaque by magnetic resonance imaging and spectroscopy.
Acta Neurol Scand Suppl. 1995;159:1-44.
3
Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Ann Neurol. 1987 Mar;21(3):300-6. doi: 10.1002/ana.410210312.
4
Blood brain barrier permeability in multiple sclerosis using labelled DTPA with PET, CT and MRI.
J Neurol Neurosurg Psychiatry. 1989 Aug;52(8):1019-20. doi: 10.1136/jnnp.52.8.1019.
5
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
Brain. 1988 Aug;111 ( Pt 4):927-39. doi: 10.1093/brain/111.4.927.
6
Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors.
Magn Reson Med. 1990 Oct;16(1):117-31. doi: 10.1002/mrm.1910160111.
7
[Magnetic resonance tomography with gadolinium DTPA in multiple sclerosis. Findings in initial manifestation and later disease stages].
Nervenarzt. 1990 Jun;61(6):356-60.
8
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.
Brain. 1990 Oct;113 ( Pt 5):1477-89. doi: 10.1093/brain/113.5.1477.
9
[Magnetic resonance imaging of disseminated sclerosis].
Ugeskr Laeger. 1994 Oct 24;156(43):6348-52.
10
Gd-DTPA-enhanced lesions in the brain of patients with acute optic neuritis.
Acta Neurol Scand. 1992 Feb;85(2):141-6. doi: 10.1111/j.1600-0404.1992.tb04014.x.
本文引用的文献
1
Trial measures in multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials.
Neurology. 1988 Jul;38(7 Suppl 2):82-3.
Zotero 插件